What this pack is
CELEXA is the brand name in this record; citalopram is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
CELEXAGeneric namecitalopram
How this medicine works
The current label describes citalopram as a selective serotonin reuptake inhibitor (SSRI), with its pharmacology understood through enhanced central serotonergic activity. Citalopram is a racemic mixture and the S-enantiomer is associated with most reuptake inhibition. This explains a pharmacologic relationship only; it does not permit milligram conversion, co-use or substitution between CELEXA and LEXAPRO, which contains escitalopram.
Read source: United States ↗Current regulatory record · reviewed 2026-08-30More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- CELEXA
- Generic name
- citalopram
- Dosage-form class
- Citalopram oral film-coated tablets: 10 mg, 20 mg or 40 mg per tablet; three 100-tablet bottles and two 100-tablet unit-dose cartons recorded separately
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
5 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Current U.S. DailyMed public label (SPL v40; effective 9 Oct 2023)
Equivalent to citalopram 10 mg per tablet; 100-tablet bottle
- Product code
- NDC 0456-4010-01
- Form and route
- CELEXA citalopram oral film-coated tablet · oral (exact tablet-product identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-30; actual marketing, stock and availability are not established.
- citalopram (supplied as citalopram hydrobromide)
- 10 mglabelled amount per tablet; not an individual's tablet count, frequency, splitting or stopping/switching instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- beige · oval film-coated tablet; unscored · imprint FP / 10 mgUnscored in this labelled presentation
United States label · Current U.S. DailyMed public label (SPL v40; effective 9 Oct 2023)
Equivalent to citalopram 20 mg per tablet; 100-tablet bottle
- Product code
- NDC 0456-4020-01
- Form and route
- CELEXA citalopram oral film-coated tablet · oral (exact tablet-product identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-30; actual marketing, stock and availability are not established.
- citalopram (supplied as citalopram hydrobromide)
- 20 mglabelled amount per tablet; not an individual's tablet count, frequency, splitting or stopping/switching instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- pink · oval film-coated tablet; scored, but the score is an appearance clue and not permission to self-split · imprint F | P / 20 mgScored appearance; this is not a self-splitting instruction
United States label · Current U.S. DailyMed public label (SPL v40; effective 9 Oct 2023)
Equivalent to citalopram 20 mg per tablet; 100-tablet unit-dose carton (10 packs × 10 tablets)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 0456-4020-63; inner blister NDC 0456-4020-11
- Form and route
- CELEXA citalopram oral film-coated tablet · oral (exact tablet-product identity field)
- Container
- unit-dose carton
- Units in each inner container
- 10 tablets per inner blisterPackage identity only; not an individual amount to take
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-30; actual marketing, stock and availability are not established.
- citalopram (supplied as citalopram hydrobromide)
- 20 mglabelled amount per tablet; not an individual's tablet count, frequency, splitting or stopping/switching instruction
- Package
- 100 tablets per unit-dose carton
- Labelled appearance
- pink · oval film-coated tablet; scored, but the score is an appearance clue and not permission to self-split · imprint F | P / 20 mgScored appearance; this is not a self-splitting instruction
United States label · Current U.S. DailyMed public label (SPL v40; effective 9 Oct 2023)
Equivalent to citalopram 40 mg per tablet; 100-tablet bottle
- Product code
- NDC 0456-4040-01
- Form and route
- CELEXA citalopram oral film-coated tablet · oral (exact tablet-product identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-30; actual marketing, stock and availability are not established.
- citalopram (supplied as citalopram hydrobromide)
- 40 mglabelled amount per tablet; not an individual's tablet count, frequency, splitting or stopping/switching instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- white · oval film-coated tablet; scored, but the score is an appearance clue and not permission to self-split · imprint F | P / 40 mgScored appearance; this is not a self-splitting instruction
United States label · Current U.S. DailyMed public label (SPL v40; effective 9 Oct 2023)
Equivalent to citalopram 40 mg per tablet; 100-tablet unit-dose carton (10 packs × 10 tablets)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 0456-4040-63; inner blister NDC 0456-4040-11
- Form and route
- CELEXA citalopram oral film-coated tablet · oral (exact tablet-product identity field)
- Container
- unit-dose carton
- Units in each inner container
- 10 tablets per inner blisterPackage identity only; not an individual amount to take
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-30; actual marketing, stock and availability are not established.
- citalopram (supplied as citalopram hydrobromide)
- 40 mglabelled amount per tablet; not an individual's tablet count, frequency, splitting or stopping/switching instruction
- Package
- 100 tablets per unit-dose carton
- Labelled appearance
- white · oval film-coated tablet; scored, but the score is an appearance clue and not permission to self-split · imprint F | P / 40 mgScored appearance; this is not a self-splitting instruction
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
CELEXA label reading: separate mg per tablet, score marks, older-age and CYP2C19 boundaries
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
The current U.S. label separately lists 10, 20 and 40 mg tablets and includes a Medication Guide, boxed warning, QT prolongation, serotonin syndrome, bleeding, hyponatraemia and discontinuation information. This module helps ordinary readers take the exact product and review questions to a pharmacist or prescriber; it gives no personal tablet count, dose change, splitting, stopping or switching plan.
- 10, 20 and 40 mg are the labelled citalopram amounts per tablet, not tablets per dose or doses per day. The 20 and 40 mg tablets are scored and the 10 mg tablet is unscored. A score is a product-appearance clue, not permission for anyone to self-split or replace a larger strength with several smaller tablets.
- The label sets a stricter professional dosing boundary for people over 60, hepatic impairment, CYP2C19 poor metabolisers or use of cimetidine/another CYP2C19 inhibitor. Mention of CYP2C19 does not mean everyone needs whole-genome screening, and the site does not select an individual's dose from genes, age or a medicine name.
- A heart-rhythm condition, low potassium or magnesium, a diuretic, fainting/palpitations or another QT-prolonging medicine on the list requires priority professional review. Older adults, people taking diuretics or those who are volume depleted also have greater hyponatraemia risk. New marked weakness, headache, confusion, unsteady gait, falls, seizures or altered awareness needs timely medical assessment.
- MAOIs, pimozide, other serotonergic medicines, aspirin/NSAIDs, antiplatelets, warfarin and other anticoagulants are priority full-list checks. Fever with agitation, tremor, muscle rigidity, diarrhoea or altered awareness, severe bleeding, breathing difficulty, fainting, or thoughts of self-harm/suicide requires immediate local emergency or crisis support.
- Do not abruptly self-stop, rotate CELEXA with LEXAPRO, ZOLOFT, PROZAC, PAXIL or another related medicine, or combine them because you feel better, unwell, missed a dose or fear a side effect. The label places discontinuation under gradual professional management; the site does not generate an individual taper.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-30
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. CELEXA citalopram oral-tablet public label and Medication Guide (SPL v40; effective 9 Oct 2023) ↗Current regulatory record · reviewed 2026-08-30
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about CELEXA (citalopram). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
CELEXA is the brand in this record and citalopram is the active-ingredient name. Check both with the dosage form (Citalopram oral film-coated tablets: 10 mg, 20 mg or 40 mg per tablet; three 100-tablet bottles and two 100-tablet unit-dose cartons recorded separately) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
HOW IT WORKS · NOT A TREATMENT PLAN
How citalopram works: serotonin-reuptake inhibition does not make SSRIs self-interchangeable
- A mechanism is not an individual outcome predictor. Symptoms, previous response, other conditions, ECG, electrolytes, liver function, age and the complete medicine list can affect professional judgement. The site does not select a medicine from a mechanism term.
- A shared SSRI class or similar brand wording does not permit rotation, combination, sharing leftovers or one-for-one milligram conversion. Check the brand, generic name, strength per tablet, dosage form, target market and prescription together.
- Whole-genome screening is not a universal prerequisite stated by this page. If the treating team believes CYP2C19, ECG, electrolytes or another test may change an individual decision, that team should explain the scope and result in the context of the exact medicine and clinical situation.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. CELEXA citalopram oral-tablet public label and Medication Guide (SPL v40; effective 9 Oct 2023) ↗Current regulatory record · reviewed 2026-08-30
- FDA Drugs@FDA: CELEXA (citalopram) NDA 020822 application and label record ↗Current regulatory record · reviewed 2026-08-30
SOURCE-TRACEABLE ARCHIVE
CELEXAcitalopram
This page includes an exact current U.S. public-label package panel for CELEXA, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval year
The current DailyMed label states Initial U.S. Approval: 1998. This records the year only and does not infer the first pack, another market's status or current supply.
DailyMed (NLM): current U.S. CELEXA citalopram oral-tablet public label and Medication Guide (SPL v40; effective 9 Oct 2023) ↗Current DailyMed SPL v40 became effective
The current label has an effective date of 9 Oct 2023 and includes the FDA-approved Medication Guide. The date identifies the file version, not anyone's start, stopping or switching date.
DailyMed (NLM): current U.S. CELEXA citalopram oral-tablet public label and Medication Guide (SPL v40; effective 9 Oct 2023) ↗
MARKET SCOPE
Market-record boundary
United States
Current brand-tablet label, Medication Guide, five outer-pack identities and three official bottle panels linkedThe dossier records the per-tablet amount, NDC, colour, imprint, score and pack count for 10, 20 and 40 mg. A label does not establish local stock, purchase availability, individual suitability or self-switching between strengths.
Mainland China, EU, Japan and other markets
Current market record not establishedNo local trade name, approval, packaging, supply, sale eligibility, originator/generic relationship or interchangeability is inferred from the U.S. brand, NDA, generic name, package panel or shared pharmacologic class.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
CELEXA 20 mg is scored. Can I split it myself to make 10 mg?
Do not decide from the score alone. It is an appearance feature of the exact tablet and does not automatically establish post-split amount, stability, prescription suitability or a stopping/switching process. Ask a pharmacist or prescriber to check the exact pack, prescription and purpose.
CELEXA and LEXAPRO have related names and mechanisms. Can their milligrams be converted?
Not from names, mechanism or milligram figures. CELEXA is citalopram and LEXAPRO is escitalopram. Their products, labels, strength systems and individual boundaries differ, and the treating professional must arrange any stopping or switching.
The label mentions CYP2C19. Does everyone need whole-genome screening?
The current label does not state whole-genome screening as a universal prerequisite. It identifies CYP2C19 poor-metaboliser status and certain inhibitors as professional dosing boundaries. The prescribing team should explain whether any testing is needed using the exact medicine, age, liver function, co-medications and other clinical information.
What if an older adult develops confusion, unsteady walking or a fall?
Contact local medical services promptly and take every pack and the complete medicine list. The label notes greater hyponatraemia risk in older adults, diuretic users or volume depletion. The site cannot diagnose the cause, and the medicine should not be abruptly self-stopped or made up. Seizure, fainting, severe palpitations, altered awareness or self-harm thoughts requires immediate local emergency or crisis support.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.